Compare RKT & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RKT | ONC |
|---|---|---|
| Founded | 1985 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3B | 40.6B |
| IPO Year | 2020 | 2015 |
| Metric | RKT | ONC |
|---|---|---|
| Price | $12.11 | $356.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | $20.40 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 26.8M | 297.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | 0.19 | ★ 0.31 |
| Revenue | N/A | ★ $238,387,000.00 |
| Revenue This Year | $66.40 | $723.76 |
| Revenue Next Year | $8.18 | $15.04 |
| P/E Ratio | ★ $63.95 | $1,177.42 |
| Revenue Growth | N/A | ★ 22179.16 |
| 52 Week Low | $12.11 | $253.95 |
| 52 Week High | $24.36 | $385.22 |
| Indicator | RKT | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 36.39 | 51.22 |
| Support Level | N/A | $327.01 |
| Resistance Level | $14.61 | $375.97 |
| Average True Range (ATR) | 0.48 | 6.24 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 2.86 | 61.99 |
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and will also be the largest mortgage servicer in the US following its acquisition of the Mr. Cooper Group.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.